Cox Troy 4

What Happened
Troy Cox, a director of SOPHiA GENETICS SA (SOPH), received equity awards on June 18, 2026: 19,724 restricted stock units (RSUs) at an indicated price of $5.46 each (value $107,693) and 28,818 stock options/derivative awards at the same per-share reference price (value $157,346). These were grants/awards (not purchases or sales), so they represent compensation/equity incentives rather than open-market trading. Total indicated value of the grants ≈ $265,039.

Key Details

• Transaction date: June 18, 2026; Form 4 filed June 22, 2026.
• Grants: 19,724 RSUs (F1) @ $5.46 = $107,693; 28,818 options/derivative awards (F2) @ $5.46 = $157,346.
• Vesting: Both awards vest 100% as of the issuer’s next scheduled annual meeting of shareholders, subject to Cox’s continued service (per footnotes F1 and F2).
• Shares owned after transaction: not disclosed in this filing.
• Filing timeliness: Form filed June 22 for a June 18 grant—no late-filing flag indicated in the filing.

Context

• RSUs: each RSU represents a contingent right to receive one ordinary share at vesting (per F1). These are not immediate share purchases.
• Options/derivative awards: represent a right to acquire shares in the future if exercised (per F2); these were grants, not exercised or sold at the time of filing.
• Such compensation grants are common for directors and are primarily a retention/compensation mechanism; they do not on their own indicate the insider bought or sold stock in the open market.